Trials Sponsors Conditions Drugs Pricing

Conditions

Plasma Cell Neoplasms

Keywords

in vivo CAR-T Cell TherapyBCMAGPRC5Dplasma cell neoplasms

Outcome Measures

Primary Outcomes (4)

Number and incidence rate with Each Grade of Cytokine Release Syndrome (CRS)
CRS severity will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading. The grade ranges from 1 to 4, where a higher grade indicates a worse outcome.
1 month after treatment
Dose-limiting toxicities (DLTs)
Dose limiting toxicity will be assessed after injection
1 month after treatment
Number and incidence rate of Each Grade of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
ICANS severity is graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading, which incorporates the Immune Effector Cell-Associated Encephalopathy (ICE) assessment. The ICE score ranges from 0 to 10, with higher scores indicating better cognitive function. ICANS grade ranges from 1 to 4, where a higher grade indicates a worse outcome.
1 month after treatment
Number and incidence rate of Treatment-Associated Adverse Events (AEs)
All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).
1 years after treatment

Secondary Outcomes (9)

Overall Objective Response Rate (ORR)
Day 14, Day 28, Month 2 , Month 3, Month 6, Month 9, Month 12, Month 18, Month24 after the treatment
overall survival (OS)
2 years after treatment
progression free survival (PFS)
2 years after treatment
duration of response (DOR)
2 years after treatment
time to progression (TTP)
2 years after treatment
+4 more secondary outcomes

Study Arms (1)

In vivo BCMA/GPRC5D Tandem Dual CAR-T

EXPERIMENTAL

Participants receive treatment of In vivo BCMA/GPRC5D Tandem Dual CAR-T cell following a 3+3 dose-escalation design.

Drug: In vivo BCMA/GPRC5D Tandem Dual CAR-T cell

Interventions

In vivo BCMA/GPRC5D Tandem Dual CAR-T cellDrug

Administration of in vivo BCMA/GPRC5D tandem dual CAR-T cells. Three dose levels (dose A, dose B, dose C) will be evaluated using a standard 3+3 dose-escalation design.

Also known as: SL4903

In vivo BCMA/GPRC5D Tandem Dual CAR-T

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Voluntary signing of informed consent by the subject or legally authorized representative, with willingness and ability to comply with scheduled visits, study treatment, laboratory tests, and other study procedures.
Diagnosis of relapsed or refractory plasma cell neoplasms meeting the following criteria:

Sponsors & Collaborators

Liping Dou
Otherlead

Study Sites (1)

Chinese PLA General Hospital

Beijing, 100853, China

RECRUITING

Bo PengCONTACT86-18701099687 lipingruirui@163.com

MeSH Terms

Conditions

Neoplasms, Plasma Cell

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasms

Study Officials

Liping DOU
Chinese PLA General Hospital
PRINCIPAL INVESTIGATOR

Central Study Contacts

Yu ZHAO

CONTACT

13601051848 zhaoyu301@126.com

Study Design

Study Type: interventional
Phase: early phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR INVESTIGATOR
PI Title: Director

Study Record Dates

First Submitted

April 20, 2026

First Posted

May 14, 2026

Study Start

May 9, 2026

Actual (reported)

Primary Completion

March 31, 2029

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (9)

Study Arms (1)

In vivo BCMA/GPRC5D Tandem Dual CAR-T

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (9)

Study Arms (1)

In vivo BCMA/GPRC5D Tandem Dual CAR-T

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations